Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and Pharmacokinetics of PF-07940369 in Healthy Adults
NCT07514156Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jul 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-07940369 in anemia (3 cohorts), sponsored by Pfizer. Primary endpoint: Number of Participants With Treatment Emergent Adverse Events at 35 days. Started Jul 2025; status: completed.
02
Drugs
PF-07940369
03
Conditions
anemia
Beyond the preview
Go deeper on NCT07514156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07514156.